Tear Film Innovations (TFI) manufactures the iLux system, an in-office device that provides targeted therapy to blocked meibomian glands for evaporative dry eye and related syndromes. The iLux received 510(k) clearance from the U.S. Food and Drug Administration in December 2017 and was unveiled to ophthalmologists and optometrists in 2018. TFI announced it completed an $8.5 million Series B Preferred Stock financing to support its growth strategy. Management said the financing "completes the capitalization for our growth strategy" and the company is making key hires to meet significant market demand for the iLux system. The company is actively commercializing the device to both the ophthalmic and optometric sectors. TFI positions the iLux as a significant new dry-eye treatment option in eye care. Tear Film Innovations (TFI) is an early-stage company developing products to treat evaporative dry eye, including Meibomian Gland Dysfunction and blepharitis. Its flagship product, the iLux® system, is an investigational in‑office device that treats blocked meibomian glands through targeted heating and compression of the eyelids. TFI recently completed a multi-site clinical study demonstrating the system's safety and efficacy, and the iLux is currently under review by the U.S. Food and Drug Administration. The company completed a $9 million Series A Preferred Stock financing to advance regulatory approvals and commercialization. Investors provide both capital and clinical support—Visionary Ventures Fund and Tigris Ventures led the round and Visionary's affiliated doctors are cited as key opinion leaders. Management stated the funding will help move the product toward commercialization in a U.S. market with more than 25 million dry eye patients.

Total raised

$18M

Funding rounds

2

Latest round

Series B

Latest activity

May 2018